Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $10.57

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $10.57, but opened at $10.90. Centessa Pharmaceuticals shares last traded at $10.33, with a volume of 63,748 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, BMO Capital Markets reaffirmed an "outperform" rating and set a $15.00 target price on shares of Centessa Pharmaceuticals in a report on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $10.00.

Centessa Pharmaceuticals Stock Performance

The company has a 50-day moving average price of $10.95 and a two-hundred day moving average price of $8.48. The company has a current ratio of 8.00, a quick ratio of 8.00 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $1.00 billion, a P/E ratio of -6.37 and a beta of 1.38.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The business had revenue of $6.85 million during the quarter. On average, equities analysts forecast that Centessa Pharmaceuticals plc will post -1.83 earnings per share for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, SVP Harris Rotman sold 4,267 shares of the firm's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.10, for a total value of $34,562.70. Following the transaction, the senior vice president now directly owns 62,625 shares of the company's stock, valued at $507,262.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Harris Rotman sold 4,267 shares of Centessa Pharmaceuticals stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.10, for a total transaction of $34,562.70. Following the completion of the transaction, the senior vice president now directly owns 62,625 shares in the company, valued at $507,262.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Karen M. Anderson sold 51,160 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $11.88, for a total transaction of $607,780.80. Following the transaction, the insider now owns 71,525 shares of the company's stock, valued at $849,717. The disclosure for this sale can be found here. Corporate insiders own 11.54% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 371.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company's stock worth $51,000 after purchasing an additional 5,037 shares during the last quarter. Quarry LP purchased a new position in Centessa Pharmaceuticals during the fourth quarter worth about $48,000. Jump Financial LLC purchased a new position in Centessa Pharmaceuticals during the fourth quarter worth about $114,000. Trexquant Investment LP purchased a new position in Centessa Pharmaceuticals during the fourth quarter worth about $114,000. Finally, Rathbones Group PLC purchased a new position in Centessa Pharmaceuticals during the third quarter worth about $203,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.